On the pathway to success: Defining subtypes of gliomas for better treatment selection and refining the meaning of success

Current Oncology Reports

Volumn 15, Issue 1, 2013, Pages 24-26

  Gilbert, Mark R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Gliomas; Molecular marker; Patient reported outcomes; Predictive factor; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER PROGNOSIS; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL TRIAL (TOPIC); GENE MUTATION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; MEDULLOBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PREDICTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; PATIENT SELECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84872403006     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0282-4     Document Type: Article

References (18)

1. Walker M, Green S, Byar D, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323-9.
2. • Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96. Seminal study providing level 1 evidence of efficacy of chemotherapy for glioblastoma.
3. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-8.
4. Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release. 2001;74:63-7.
5. •• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110. Integration of Cancer Genome Atlas data into cogent subgroups of glioblastoma.
6. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-73.
7. Niu N, Qin Y, Fridley BL, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 2010;20:1482-92.
8. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res. 2004;10:4303-6.
9. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012;488:106-10.
10. •• Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061-8. Comprehensive publication of the Cancer Genome Atlas data for glioblastoma.
11. •• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-73. Report of the discovery of IDH1 and IDH2 in glioblastoma with important prognostic and biologic importance.
12. • van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed Anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group study 26951. J Clin Oncol. 2012. doi: 10.1200/JCO.2012.43.2229. Long-term results demonstrate predictive importance of 1p/19q loss. Findings complementary to those of [13].
13. • Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012. doi: 10.1200/JCO.2012.43.2674. Long-term results demonstrate predictive importance of 1p/19q loss. Findings complementary to those of [12].
14. Cairncross JG. Aggressive oligodendroglioma: a chemosensitive tumor. Recent Results Cancer Res. 1994;135:127-33.
15. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J National Cancer Inst. 1998;90:1473-9.
16. Armstrong TS, Mendoza T, Gning I, et al. Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). J Neurooncol. 2006;80:27-35.
17. Armstrong TS, Wefel JS, Wang M, et al. Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. J Clin Oncol. 2011;29:144s.
18. Efficace F, Bottomley A. Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer. 2002;38:1824-31.